Over the last 7 days, the United States market has remained flat, yet it is up 7.2% over the past year with earnings projected to grow by 14% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive economic trends.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.40% 34.10% ★★★★★★ Arcutis Biotherapeutics 26.42% 58.25% ★★★★★★ Ardelyx 20.63% 59.87% ★★★★★★ Travere Therapeutics 28.83% 64.80% ★★★★★★ TG Therapeutics 25.99% 38.42% ★★★★★★ Alnylam Pharmaceuticals 23.67% 61.11% ★★★★★★ AVITA Medical 27.81% 55.17% ★★★★★★ Alkami Technology 22.46% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.34% 120.49% ★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Organogenesis Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of approximately $674.86 million.

Operations: The company generates revenue primarily from its regenerative medicine segment, amounting to $482.04 million.

Organogenesis Holdings has demonstrated a notable uptick in financial performance, with a significant jump in quarterly sales from $99.65 million to $126.66 million and a swing from a net loss to a net income of $7.67 million. This growth is underscored by their recent inclusion in the S&P Biotechnology Select Industry Index, signaling increased market recognition. Despite challenges in maintaining profitability, with earnings expected to grow by 73.29% annually, the company's strategic focus on R&D might bolster its competitive edge; however, it’s worth noting that their revenue growth rate of 8.6% per year slightly outpaces the broader US market's 8.4%. Looking ahead into 2025, Organogenesis anticipates revenues between $480 million and $535 million, suggesting confidence in sustained growth despite past volatility in earnings and share price movements.

Take a closer look at Organogenesis Holdings' potential here in our health report. Explore historical data to track Organogenesis Holdings' performance over time in our Past section.NasdaqCM:ORGO Earnings and Revenue Growth as at May 2025

TeraWulf

Simply Wall St Growth Rating: ★★★★★☆

Overview: TeraWulf Inc., along with its subsidiaries, functions as a digital asset technology company in the United States and has a market cap of approximately $1.15 billion.

Story Continues

Operations: TeraWulf generates revenue primarily through digital currency mining, with this segment contributing $140.05 million. The company operates within the digital asset technology sector in the United States.

TeraWulf Inc., navigating through a transformative phase, reported a doubling of its annual sales to $140.05 million, up from $69.23 million, reflecting robust growth momentum in the tech sector. Despite a net loss reduction to $72.42 million from $73.42 million year-over-year, the company has actively engaged in shareholder value initiatives by repurchasing 24 million shares for $150 million. With revenue growth forecasted at an impressive 40% annually and earnings expected to surge by 77.49% per year, TeraWulf's aggressive expansion into high-demand tech markets is evident as it aims for profitability within three years amidst volatile market conditions and significant R&D investments aimed at innovation and market competitiveness.

Delve into the full analysis health report here for a deeper understanding of TeraWulf. Gain insights into TeraWulf's past trends and performance with our Past report.NasdaqCM:WULF Earnings and Revenue Growth as at May 2025

IREN

Simply Wall St Growth Rating: ★★★★★☆

Overview: IREN Limited is a company that owns and operates bitcoin mining data centers, with a market capitalization of $1.39 billion.

Operations: The company generates revenue from building and operating data center sites specifically for bitcoin mining, with a reported revenue of $285.77 million.

Amidst a dynamic tech landscape, IREN Limited has demonstrated notable agility and growth, particularly in its Bitcoin mining operations. In April 2025 alone, the company mined 579 Bitcoin, generating revenues of $50.1 million with a revenue per Bitcoin at an impressive $86,522. This performance is part of a broader expansion strategy where IREN increased its mining capacity to 40 EH/s and is on track to reach 50 EH/s by mid-2025. These developments are underscored by significant investments in R&D and infrastructure enhancements aimed at scaling operations efficiently while boosting profitability projections. With earnings expected to grow by an annual rate of 101.8% and revenue forecasted to increase by 45.9% annually, IREN is strategically positioning itself within the high-growth tech sector through innovative expansions and robust financial strategies.

Dive into the specifics of IREN here with our thorough health report. Assess IREN's past performance with our detailed historical performance reports.NasdaqGS:IREN Revenue and Expenses Breakdown as at May 2025

Where To Now?

Click here to access our complete index of 231 US High Growth Tech and AI Stocks. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:ORGONasdaqCM:WULF and NasdaqGS:IREN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments